- Home
- IQI vs PCRX Comparison
IQI vs PCRX Comparison
Compare IQI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQI
- PCRX
- Stock Information
- Founded
- IQI 1992
- PCRX 2006
- Country
- IQI United States
- PCRX United States
- Employees
- IQI N/A
- PCRX N/A
- Industry
- IQI Finance Companies
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- IQI Finance
- PCRX Health Care
- Exchange
- IQI Nasdaq
- PCRX Nasdaq
- Market Cap
- IQI 529.4M
- PCRX 1.2B
- IPO Year
- IQI N/A
- PCRX 2011
- Fundamental
- Price
- IQI $9.34
- PCRX $22.90
- Analyst Decision
- IQI
- PCRX Buy
- Analyst Count
- IQI 0
- PCRX 8
- Target Price
- IQI N/A
- PCRX $28.38
- AVG Volume (30 Days)
- IQI 162.1K
- PCRX 525.8K
- Earning Date
- IQI 01-01-0001
- PCRX 07-29-2025
- Dividend Yield
- IQI 4.61%
- PCRX N/A
- EPS Growth
- IQI N/A
- PCRX N/A
- EPS
- IQI N/A
- PCRX N/A
- Revenue
- IQI N/A
- PCRX $702,772,000.00
- Revenue This Year
- IQI N/A
- PCRX $7.92
- Revenue Next Year
- IQI N/A
- PCRX $11.02
- P/E Ratio
- IQI N/A
- PCRX N/A
- Revenue Growth
- IQI N/A
- PCRX 3.08
- 52 Week Low
- IQI $8.05
- PCRX $11.16
- 52 Week High
- IQI $10.00
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- IQI 45.62
- PCRX 35.82
- Support Level
- IQI $9.35
- PCRX $22.82
- Resistance Level
- IQI $9.54
- PCRX $23.83
- Average True Range (ATR)
- IQI 0.08
- PCRX 0.74
- MACD
- IQI 0.00
- PCRX -0.02
- Stochastic Oscillator
- IQI 20.00
- PCRX 6.22
About IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.